CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

NTC has been recognized by Life Sciences Review Magazine as the exclusive recipient of “Top 10 Therapeutics Companies in Europe - 2024,” based on our proprietary methodology, reflecting its position in the industry. This profile has been developed by the Life Sciences Review research and editorial team based on insights from an interview with , .

NTC
Bridging Gaps in Patient Care with Innovative Therapeutic Solutions

NTC

Riccardo Carbucicchio, NTC | Life Science Review | Top Therapeutics Companies in EuropeRiccardo Carbucicchio, CEO
NTC is pioneering advancements in the pharmaceutical industry by addressing and fulfilling critical unmet medical needs.

There’s a growing need for effective therapeutic solutions backed by strong clinical data to bridge the gaps in patient care. Engaging in meaningful dialogues with healthcare professionals and advisory boards, NTC identifies these gaps. Leveraging the insights gained from these interactions, the R&D-driven company oversees the research, development, registration, and commercialization of high-quality drugs, medical devices, and food supplements.

“At the forefront of our process is the understanding that the starting point of a solution is a doctor’s recommendation. We possess the ability to listen to and deeply understand the needs of that customer segment,” says Riccardo Carbucicchio, CEO.

Under Carbucicchio’s leadership, NTC has carved a niche in the global pharmaceutical sector, particularly in ophthalmology, while also extending its expertise to other therapeutic areas, including gynecology, gastroenterology, and pediatrics. Having distributors and partners in over 100 countries, the company delivers impactful solutions that are relevant and effective for providers and their patients.

A Collaborative Approach to Developing Effective Solutions

NTC follows a strategic method to ensure the successful development of its solutions, collaborating with providers to drive development and manufacturing. The process begins with identifying the healthcare challenges that demand innovative therapies. Once a need is established, the focus shifts to determining the appropriate technology and product that would conceptually address it, along with gathering the necessary data for further development.

It teams up with contract research organizations to conduct comprehensive clinical trials. These partnerships confirm the efficacy and safety of products, ensuring compliance with global regulatory standards. Helping to establish its credibility in the market, NTC has a strong history of publishing research. Many contributors to these studies belong to various European countries, showcasing the collective efforts involved in their research.

With strong development skills and extensive regulatory knowledge, NTC is well-equipped to design and validate its innovative ideas. It associates with reputable contract development and manufacturing organizations with the right technologies to bring their concepts to life. The result is a pipeline of products that address pressing medical needs while adhering to the highest standards of efficacy and safety.

The products are commercialized globally through a B2B model that includes partnerships with over 200 licensees and distributors in more than 100 countries. This comprehensive approach—from need identification to product development, clinical validation, and global distribution—ensures that it continuously delivers innovative, high-quality solutions that align with the evolving needs of healthcare providers and patients worldwide.

At the forefront of our process is the understanding that the starting point of a solution is a doctor’s recommendation. We possess the ability to listen to and deeply understand the needs of that customer segment

Improving Patient Care Through Innovation and ESG Leadership

Throughout its path to commercialization, NTC relies on a team of professionals with decades of experience, many of whom were recruited from large multinational companies. These experts collaborate with the leadership team to transform insights and ideas gathered from the medical community into effective products.

A notable achievement of the NTC team is the development of a combination drug designed for patients undergoing post-cataract surgery. The innovative solution in eye drops effectively reduces the reliance on antibiotics while providing adequate prevention against potentially severe side effects associated with the surgery. Backed by extensive clinical trials and large data sets, the product has gained international recognition and is currently marketed in over 60 countries. NTC aims to expand the product’s reach to approximately 90 countries in the next 24 months.

NTC strives to deliver its solutions while staying deeply committed to environmental, social, and governance (ESG) principles. It prioritizes the development of products that minimize carbon footprints and promote sustainability. ESG considerations are embedded from the earliest stages of product development, ensuring responsible practices throughout the manufacturing process. This commitment to sustainability is a guiding principle within the organization and is an important aspect to highlight in discussions about its mission and values.

As NTC continues to innovate and expand its product offerings, it remains steadfast in its dedication to enhancing patient care and making a positive impact on global healthcare—one solution at a time.

Top 10 Therapeutics Companies in Europe - 2024
Current Issue

Company : NTC

Management
Riccardo Carbucicchio, CEO

Thank you for Subscribing to Life Science Review Weekly Brief

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/ntc